3results about How to "Clear activity" patented technology

This invention discloses a turtle peptide with angiotensin-converting enzyme (ACE) inhibitory activity, its preparation, and its application, belonging to the field of biotechnology. Using turtle as raw material, this invention obtains peptide components with a molecular weight less than 5 kDa through enzymatic hydrolysis and ultrafiltration. Sequencing reveals three peptide sequences with ACE inhibitory activity: AAGPAGGNLN, EAGAQGPPGA, and GARGDK. In vitro activity experiments verified the ACE inhibitory function of the three turtle peptides. The turtle peptide combination prepared by this invention exhibits significant ACE inhibitory activity and can be used to develop functional foods or antihypertensive drugs. Furthermore, the preparation method is environmentally friendly, efficient, and suitable for industrial production.

The invention provides a compound probiotic composition and application thereof in a product for improving intestinal health, the compound probiotic composition is prepared from lactobacillus rhamnosus GG, lactic acid bacteria compound powder, plant lactobacillus GOLDGUT-LP1024 and lactobacillus paracasei GOLDGUT-LC12345, and the lactobacillus rhamnosus GG, the lactic acid bacteria compound powder, the plant lactobacillus GOLDGUT-LC12345 and the lactobacillus paracasei GOLDGUT-LC12345 are added into the compound probiotic composition. The lactic acid bacteria compound powder is prepared by mixing bifidobacterium longum subsp. Longum BORI, lactobacillus acidophilus AD031, bifidobacterium bifidum BGN4, bifidobacterium animalis subsp. Lactis AD011 and bifidobacterium longum subsp. Infantis IBS007; the plant lactobacillus GOLDGUT-LP1024 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the plant lactobacillus GOLDGUT-LP1024 is CGMCC No.28801. The compound probiotic composition provided by the invention can improve the immune function and metabolism function of the intestinal tract so as to improve the health of the intestinal tract and relieve antibiotic-related diarrhea.

This invention discloses the application of *Lactobacillus mucosa* vesicles in the preparation of drugs for treating MAFLD, belonging to the field of microbial medicine. The *Lactobacillus mucosa* strain is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC NO.37136, and its 16S rDNA gene sequence is shown in SEQ ID NO: 1. The *Lactobacillus mucosa* strain was isolated from fecal samples of healthy adults. This strain exhibits significant antioxidant, anti-inflammatory, and lipid metabolism regulating activities in vitro. Its secreted EVs are non-cytotoxic and non-immunogenic in vivo, and animal experiments have verified its good in vivo safety and liver-targeted enrichment characteristics.